Lilly rises after Novo reports CagriSema beats 5mg tirzepatide
Novo Nordisk said CagriSema beat tirzepatide’s 5-milligram dose in a late-stage diabetes study. Lilly shares still climbed about 1.2% to $1,166.74.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.